1. Home
  2. MAIN vs GRFS Comparison

MAIN vs GRFS Comparison

Compare MAIN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Main Street Capital Corporation

MAIN

Main Street Capital Corporation

HOLD

Current Price

$54.84

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$7.84

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAIN
GRFS
Founded
2007
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.8B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MAIN
GRFS
Price
$54.84
$7.84
Analyst Decision
Hold
Hold
Analyst Count
7
2
Target Price
$61.57
$10.15
AVG Volume (30 Days)
697.2K
682.6K
Earning Date
04-30-2026
01-01-0001
Dividend Yield
7.90%
1.79%
EPS Growth
N/A
N/A
EPS
3.95
N/A
Revenue
N/A
N/A
Revenue This Year
$4.28
$5.33
Revenue Next Year
$5.33
$6.50
P/E Ratio
$13.83
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$47.00
$6.19
52 Week High
$67.77
$11.14

Technical Indicators

Market Signals
Indicator
MAIN
GRFS
Relative Strength Index (RSI) 34.96 27.72
Support Level N/A $7.64
Resistance Level $58.86 $9.11
Average True Range (ATR) 1.66 0.29
MACD -0.20 -0.12
Stochastic Oscillator 15.73 2.99

Price Performance

Historical Comparison
MAIN
GRFS

About MAIN Main Street Capital Corporation

Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: